Intech Biopharm Corporation (TPEX:6461)

Intech Biopharm Statistics

Total Valuation

Intech Biopharm has a market cap or net worth of TWD 2.73 billion. The enterprise value is 3.53 billion.

Market Cap	2.73B
Enterprise Value	3.53B

Important Dates

The next estimated earnings date is Tuesday, August 11, 2026.

Earnings Date	Aug 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Intech Biopharm has 178.41 million shares outstanding. The number of shares has increased by 29.83% in one year.

Current Share Class	178.41M
Shares Outstanding	178.41M
Shares Change (YoY)	+29.83%
Shares Change (QoQ)	+8.78%
Owned by Insiders (%)	1.00%
Owned by Institutions (%)	5.88%
Float	100.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.23
PB Ratio	2.75
P/TBV Ratio	2.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-8.56
EV / Sales	30.05
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.98

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 1.00.

Current Ratio	0.96
Quick Ratio	0.52
Debt / Equity	1.00
Debt / EBITDA	n/a
Debt / FCF	-2.53
Interest Coverage	-11.84

Financial Efficiency

Return on equity (ROE) is -47.98% and return on invested capital (ROIC) is -11.49%.

Return on Equity (ROE)	-47.98%
Return on Assets (ROA)	-10.34%
Return on Invested Capital (ROIC)	-11.49%
Return on Capital Employed (ROCE)	-20.29%
Weighted Average Cost of Capital (WACC)	4.70%
Revenue Per Employee	1.22M
Profits Per Employee	-4.30M
Employee Count	96
Asset Turnover	0.05
Inventory Turnover	2.13

Taxes

In the past 12 months, Intech Biopharm has paid 6.80 million in taxes.

Income Tax	6.80M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.16% in the last 52 weeks. The beta is 0.22, so Intech Biopharm's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	-16.16%
50-Day Moving Average	17.65
200-Day Moving Average	18.28
Relative Strength Index (RSI)	26.97
Average Volume (20 Days)	208,142

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Intech Biopharm had revenue of TWD 117.49 million and -412.53 million in losses. Loss per share was -2.32.

Revenue	117.49M
Gross Profit	-112.72M
Operating Income	-388.83M
Pretax Income	-405.73M
Net Income	-412.53M
EBITDA	-298.33M
EBIT	-388.83M
Loss Per Share	-2.32

Balance Sheet

The company has 192.89 million in cash and 993.44 million in debt, with a net cash position of -800.55 million or -4.49 per share.

Cash & Cash Equivalents	192.89M
Total Debt	993.44M
Net Cash	-800.55M
Net Cash Per Share	-4.49
Equity (Book Value)	991.64M
Book Value Per Share	5.56
Working Capital	-15.60M

Cash Flow

In the last 12 months, operating cash flow was -347.27 million and capital expenditures -45.62 million, giving a free cash flow of -392.89 million.

Operating Cash Flow	-347.27M
Capital Expenditures	-45.62M
Depreciation & Amortization	90.50M
Net Borrowing	-24.29M
Free Cash Flow	-392.89M
FCF Per Share	-2.20

Margins

Gross Margin	-95.94%
Operating Margin	-330.95%
Pretax Margin	-345.34%
Profit Margin	n/a
EBITDA Margin	-253.92%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Intech Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.83%
Shareholder Yield	-29.83%
Earnings Yield	-15.11%
FCF Yield	-14.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5